-

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

The Company to host an earnings conference call via webcast

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period.

Conference Call and Webcast Details

The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Tuesday, July 29th, 2025, at 10:30AM ET.

The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx.

***Participant Dial-In Details***

Joining by Phone
USA / International Toll +1 (646) 307-1963
USA - Toll-Free (800) 715-9871
Participants call one of the allocated dial-in numbers and advise the Operator of either the Conference ID 3224490 or Conference Name.

Webcast Attendee URL
https://events.q4inc.com/attendee/710965397

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company’s LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology.

Contacts

Investor Relations Contact
Louie Toma
Managing Director, CORE IR
investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$nvda
$xbi
Hashtags
#AI
#DrugDiscovery
#TechBio
#antibodies
#foundationai
#generativeai
#llm

Contacts

Investor Relations Contact
Louie Toma
Managing Director, CORE IR
investors@ipatherapeutics.com

Social Media Profiles
Linkedin
IPA on X
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

BOSTON--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company’s pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Ther...

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies what a horizontal ontology cannot: a governed, model-agnostic representation of what biology does, available from the first day of a de...

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced the appointment of Kim Remizowski to its Board of Directors as an independent director, effective September 29, 2026. Mr. Remizowski will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The Board has determined that he qualifies as an independent director under Nasdaq listing rules and as an audit committee financial expert under a...
Back to Newsroom